NEW YORK, Oct. 1 – Houston-based investment banking firm Sanders Morris Harris has closed its $11 million LifeSciences Opportunity Fund, which will look to invest in early- and middle-stage functional genomics and proteomics companies.
"Our first LifeSciences Fund is focused on investing in companies with technologies that have a high likelihood of playing a key role in commercializing new scientific discoveries arising from the recent historical developments in biomedical research such as the human genome project," James Gale, a managing director at the firm, said in a statement released Friday.
The fund, which will also look to invest in drug delivery and gene therapy technologies, is designed to give individual investors the chance to invest in emerging medical technology.
So far, the fund has made two investments. Sanders Morris Harris has over $3 billion under management.